Lancet market seen reaching $4.71 billion by 2030

The lancet market is projected to grow from $3.11 billion in 2026 to $4.71 billion by 2030, according to The Business Research Company. Demand is being driven by diabetes care, safer blood sampling tools and growing use of home testing and point-of-care diagnostics.

Why it matters: - Lancets are a core tool for blood sampling and diabetes monitoring, so market growth reflects broader demand for safer, more precise at-home and clinical testing. - The forecast points to sustained demand for small medical devices as diabetes prevalence, homecare testing and point-of-care diagnostics expand.

What happened: - The Business Research Company released its 2026 lancet market report covering market size, trends and global forecasts for 2026-2035. - The lancet market is estimated at $3.11 billion in 2026, up from $2.8 billion in 2025. - The market is projected to reach $4.71 billion by 2030. - The report puts the market on a 10.9% CAGR through 2030. - North America was the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Rising diabetes prevalence remains a major demand driver because lancets support fingertip blood glucose monitoring. - Lancets are also used for abscess drainage and minor surgical procedures. - The report cites growth in hospital infrastructure, higher awareness of blood testing, demand for point-of-care diagnostic tools and safer lancet devices as historical growth drivers. - Looking ahead, the report points to innovation in lancet design, wider use of homecare testing kits, integration with digital health platforms, expansion into emerging markets and more regulatory support for safety-focused medical devices. - The report flags miniaturization of medical instruments, patient safety, home healthcare, point-of-care diagnostics and sustainable medical tools as key trends. - In June 2024, the UK National Health Service reported that more than 549,000 additional people in England were identified as at risk for type 2 diabetes in 2023. - That brought the number registered with general practitioners for pre-diabetes or non-diabetic hyperglycemia to 3,615,330, up nearly 20% from 3,065,825 in 2022. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - The report offers a free sample and the full market report through the company's website: Download a free sample of the lancet market report and View the full lancet market report.

Between the lines: - The forecast suggests the lancet market is benefiting from a shift toward safer, simpler and more distributed testing outside traditional labs. - Diabetes care remains the clearest demand anchor, but the broader mix of homecare, digital health and sustainability trends points to a wider device upgrade cycle. - North America’s lead and Asia-Pacific’s expected acceleration suggest a market that is both mature and still expanding geographically.

What's next: - The lancet market is expected to keep expanding steadily through 2030 as home testing and digital health adoption increase. - Product development will likely focus on safety, miniaturization and environmentally friendlier designs. - Regional growth should be strongest in Asia-Pacific as emerging markets adopt more diagnostic tools.